How many drugs treat Pyoderma gangrenosum?

Drug Landscape tracks 5 marketed treatments for Pyoderma gangrenosum (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pyoderma-gangrenosum.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pyoderma gangrenosum — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pyoderma gangrenosum (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pyoderma gangrenosum, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Abrilada	Adalimumab-Afzb	AbbVie	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
Humira	ADALIMUMAB	AbbVie	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Lamprene	clofazimine	Novartis	Antimycobacterial	ATP-binding cassette sub-family G member 2	1986-01-01
CYLTEZO	ADALIMUMAB-ADBM	BOEHRINGER INGELHEIM		Tumor necrosis factor
Humira	Humira	Sohag University		Tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 2 drugs in Pyoderma gangrenosum
BOEHRINGER INGELHEIM · 1 drug in Pyoderma gangrenosum
Novartis · 1 drug in Pyoderma gangrenosum
Sohag University · 1 drug in Pyoderma gangrenosum

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pyoderma gangrenosum:

Cite this brief

Drug Landscape (2026). Pyoderma gangrenosum — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pyoderma-gangrenosum. Accessed 2026-06-10.

Pyoderma gangrenosum full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing